● Recruiting

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Condition: Advanced Solid Tumors · Sponsor: Samsung Bioepis Co., Ltd.

PhasePhase 1

Planned participants149

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

This description comes directly from the study's public registry record.

Talk to the study team

Samsung Bioepis · +82-32-728-0114 · bioepisinfo@samsung.com

Always discuss trial participation with your own doctor first.

Locations (6)

Research Site	Scottsdale, Arizona, United States	Recruiting
Research Site	Fairfax, Virginia, United States	Recruiting
Research Site	Adelaide, Australia	Recruiting
Research Site	Melbourne, Australia	Recruiting
Research Site	Barcelona, Spain	Recruiting
Research Site	Madrid, Spain	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07524348